{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:38:21Z","timestamp":1782261501252,"version":"3.54.5"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T00:00:00Z","timestamp":1654905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T00:00:00Z","timestamp":1654905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N013638\/1"],"award-info":[{"award-number":["MR\/N013638\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The World Health Organization (WHO) recommends surveillance of molecular markers of resistance to anti-malarial drugs. This is particularly important in the case of mass drug administration (MDA), which is endorsed by the WHO in some settings to combat malaria. Dihydroartemisinin-piperaquine (DHA-PPQ) is an artemisinin-based combination therapy which has been used in MDA. This review analyses the impact of MDA with DHA-PPQ on the evolution of molecular markers of drug resistance. The review is split into two parts. Section I reviews the current evidence for different molecular markers of resistance to DHA-PPQ. This includes an overview of the prevalence of these molecular markers in <jats:italic>Plasmodium falciparum<\/jats:italic> Whole Genome Sequence data from the MalariaGEN Pf3k project. Section II is a systematic literature review of the impact that MDA with DHA-PPQ has had on the evolution of molecular markers of resistance. This systematic review followed PRISMA guidelines. This review found that despite being a recognised surveillance tool by the WHO, the surveillance of molecular markers of resistance following MDA with DHA-PPQ was not commonly performed. Of the total 96 papers screened for eligibility in this review, only 20 analysed molecular markers of drug resistance. The molecular markers published were also not standardized. Overall, this warrants greater reporting of molecular marker prevalence following MDA implementation. This should include putative <jats:italic>pfcrt<\/jats:italic> mutations which have been found to convey resistance to DHA-PPQ in vitro<jats:italic>.<\/jats:italic><\/jats:p>","DOI":"10.1186\/s12936-022-04181-y","type":"journal-article","created":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T11:03:04Z","timestamp":1654945384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["How has mass drug administration with dihydroartemisinin-piperaquine impacted molecular markers of drug resistance? A systematic review"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2843-9085","authenticated-orcid":false,"given":"Sophie","family":"Moss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Ma\u0144ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Campino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taane G.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Last","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,11]]},"reference":[{"key":"4181_CR1","volume-title":"World malaria report 2021","author":"WHO","year":"2021","unstructured":"WHO. World malaria report 2021. Geneva: World Health Organization; 2021."},{"key":"4181_CR2","volume-title":"Mass drug administration, mass screening and treatment and focal screening and treatment for malaria. Malaria policy advisory committee meeting","author":"WHO","year":"2015","unstructured":"WHO. Mass drug administration, mass screening and treatment and focal screening and treatment for malaria. Malaria policy advisory committee meeting. Geneva: World Health Organization; 2015."},{"key":"4181_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/0169-4758(88)90042-7","volume":"4","author":"D Payne","year":"1988","unstructured":"Payne D. Did medicated salt hasten the spread of chloroquine resistance in Plasmodium falciparum? Parasitol Today. 1988;4:112\u20135.","journal-title":"Parasitol Today"},{"key":"4181_CR4","volume-title":"World malaria report 2020","author":"WHO","year":"2020","unstructured":"WHO. World malaria report 2020. Geneva: World Health Organization; 2020."},{"key":"4181_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2021.105828","volume":"216","author":"L Slater","year":"2021","unstructured":"Slater L, Betson M, Ashraf S, Sargison N, Chaudhry U. Current methods for the detection of antimalarial drug resistance in Plasmodium parasites infecting humans. Acta Trop. 2021;216: 105828.","journal-title":"Acta Trop"},{"key":"4181_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/nyas.12766","volume":"1342","author":"S Takala-Harrison","year":"2015","unstructured":"Takala-Harrison S, Laufer MK. Antimalarial drug resistance in Africa: key lessons for the future. Ann N Y Acad Sci. 2015;1342:62\u20137.","journal-title":"Ann N Y Acad Sci"},{"key":"4181_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4269\/ajtmh.1996.54.62","volume":"54","author":"S Looareesuwan","year":"1996","unstructured":"Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Canfield CJ. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg. 1996;54:62\u20136.","journal-title":"Am J Trop Med Hyg"},{"key":"4181_CR8","first-page":"285","volume":"9","author":"JH Edgcomb","year":"1950","unstructured":"Edgcomb JH, Arnold J, Yount Eh Jr, Alving AS, Eichelberger L, Jeffery GM, et al. Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report. J Natl Malar Soc. 1950;9:285\u201392.","journal-title":"J Natl Malar Soc"},{"key":"4181_CR9","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1056\/NEJMc0805011","volume":"359","author":"H Noedl","year":"2008","unstructured":"Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619\u201320.","journal-title":"N Engl J Med"},{"key":"4181_CR10","first-page":"1125","volume-title":"Saving lives, buying time: economics of malaria drugs in an age of resistance","author":"Institute of Medicine (US) Committee on the Economics of Antimalarial Drugs","year":"2004","unstructured":"Institute of Medicine (US) Committee on the Economics of Antimalarial Drugs. Saving lives, buying time: economics of malaria drugs in an age of resistance. Washington (DC): National Academies Press (US); 2004. p. 1125\u20137."},{"key":"4181_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0165-6147(99)01302-4","volume":"20","author":"MA van Agtmael","year":"1999","unstructured":"van Agtmael MA, Eggelte TA, van Boxtel CJ. Artemisinin drugs in the treatment of malaria: from medicinal herb to registered medication. Trends Pharmacol Sci. 1999;20:199\u2013205.","journal-title":"Trends Pharmacol Sci"},{"key":"4181_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1055\/s-2007-971424","volume":"44","author":"T You-you","year":"1982","unstructured":"You-you T, Mu-yun N, Yurong Z, Lan-na L, Shu-lian G, Mu-qun Z, et al. Studies on the constituents of Artemisia annua. J Med Plant Res. 1982;44:143\u20135.","journal-title":"J Med Plant Res"},{"key":"4181_CR13","doi-asserted-by":"publisher","first-page":"10111","DOI":"10.1038\/ncomms10111","volume":"6","author":"J Wang","year":"2015","unstructured":"Wang J, Zhang CJ, Chia WN, Loh CC, Li Z, Lee YM, He Y, Yuan LX, Lim TK, et al. Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nat Commun. 2015;6:10111.","journal-title":"Nat Commun"},{"key":"4181_CR14","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.pt.2020.03.010","volume":"36","author":"T Spielmann","year":"2020","unstructured":"Spielmann T, Gras S, Sabitzki R, Meissner M. Endocytosis in Plasmodium and toxoplasma parasites. Trends Parasitol. 2020;36:520\u201332.","journal-title":"Trends Parasitol"},{"key":"4181_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/tropicalmed4020089","volume":"4","author":"LE Heller","year":"2019","unstructured":"Heller LE, Roepe PD. Artemisinin-based antimalarial drug therapy: molecular pharmacology and evolving resistance. Trop Med Infect Dis. 2019;4:89.","journal-title":"Trop Med Infect Dis"},{"key":"4181_CR16","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/nature01813","volume":"424","author":"U Eckstein-Ludwig","year":"2003","unstructured":"Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, Kimura M, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature. 2003;424:957\u201361.","journal-title":"Nature"},{"key":"4181_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2133\/dmpk.23.158","volume":"23","author":"DT Le Thi","year":"2008","unstructured":"Le Thi DT, Le NH, Nguyen CH, Phan Thi D, Na-Bangchang K. Pharmacokinetics of a five-day oral dihydroartemisinin monotherapy regimen in patients with uncomplicated falciparum malaria. Drug Metab Pharmacokinet. 2008;23:158\u201364.","journal-title":"Drug Metab Pharmacokinet"},{"key":"4181_CR18","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1128\/AAC.01717-08","volume":"53","author":"DV Nguyen","year":"2009","unstructured":"Nguyen DV, Nguyen QP, Nguyen ND, Le TT, Nguyen TD, Dinh DN, Nguyen TX, et al. Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam. Antimicrob Agents Chemother. 2009;53:3534\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"4181_CR19","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1128\/AAC.46.4.1125-1127.2002","volume":"46","author":"PN Newton","year":"2002","unstructured":"Newton PN, van Vugt M, Teja-Isavadharm P, Siriyanonda D, Rasameesoroj M, et al. Comparison of oral artesunate and dihydroartemisinin antimalarial bioavailabilities in acute falciparum malaria. Antimicrob Agents Chemother. 2002;46:1125\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"4181_CR20","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025510","author":"DF Wirth","year":"2017","unstructured":"Wirth DF, Alonso PL. Malaria biology in the era of eradication. Cold Spring Harbor Perspect Med. 2017. https:\/\/doi.org\/10.1101\/cshperspect.a025510.","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"4181_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41467-018-05652-0","volume":"9","author":"LS Ross","year":"2018","unstructured":"Ross LS, Dhingra SK, Mok S, Yeo T, Wicht KJ, K\u00fcmpornsin K, et al. Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine. Nat Commun. 2018;9:25\u20138.","journal-title":"Nat Commun"},{"key":"4181_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1128\/mBio.00303-17","volume":"8","author":"SK Dhingra","year":"2017","unstructured":"Dhingra SK, Redhi D, Combrinck JM, Yeo T, Okombo J, Henrich PP, et al. A variant PfCRT isoform can contribute to Plasmodium falciparum resistance to the first-line partner drug piperaquine. mBio. 2017;8:3.","journal-title":"mBio"},{"key":"4181_CR23","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3109\/01913123.2011.601405","volume":"35","author":"N Sachanonta","year":"2011","unstructured":"Sachanonta N, Chotivanich K, Chaisri U, Turner GD, Ferguson DJ, Day NP, et al. Ultrastructural and real-time microscopic changes in P. falciparum-infected red blood cells following treatment with antimalarial drugs. Ultrastruct Pathol. 2011;35:214\u201325.","journal-title":"Ultrastruct Pathol"},{"key":"4181_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41586-019-1795-x","volume":"576","author":"J Kim","year":"2019","unstructured":"Kim J, Tan YZ, Wicht KJ, Erramilli SK, Dhingra SK, Okombo J, Vendome J, et al. Structure and drug resistance of the Plasmodium falciparum transporter PfCRT. Nature. 2019;576:315\u201320.","journal-title":"Nature"},{"key":"4181_CR25","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1056\/NEJMc1403007","volume":"371","author":"DL Saunders","year":"2014","unstructured":"Saunders DL, Vanachayangkul P, Lon C, U.S. Army Military Malaria Research Program, National Center for Parasitology, Entomology, and Malaria Control (CNM), Royal Cambodian Armed Forces. Dihydroartemisinin-piperaquine failure in Cambodia. N Engl J Med. 2014;371:484\u20135.","journal-title":"N Engl J Med"},{"key":"4181_CR26","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S1473-3099(19)30391-3","volume":"19","author":"RW van der Pluijm","year":"2019","unstructured":"van der Pluijm RW, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, et al. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect Dis. 2019;19:952\u201361.","journal-title":"Lancet Infect Dis"},{"key":"4181_CR27","volume-title":"Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010\u20132019)","author":"WHO","year":"2020","unstructured":"WHO. Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010\u20132019). Geneva: World Health Organization; 2020."},{"key":"4181_CR28","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1473-3099(16)30415-7","volume":"17","author":"B Witkowski","year":"2017","unstructured":"Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J, et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype\u2013genotype association study. Lancet Infect Dis. 2017;17:174\u201383.","journal-title":"Lancet Infect Dis"},{"key":"4181_CR29","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S1473-3099(16)30409-1","volume":"17","author":"R Amato","year":"2017","unstructured":"Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson RD, et al. Genetic markers associated with dihydroartemisinin\u2013piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype\u2013phenotype association study. Lancet Infect Dis. 2017;17:164\u201373.","journal-title":"Lancet Infect Dis"},{"key":"4181_CR30","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/s41467-018-04104-z","volume":"9","author":"S Bopp","year":"2018","unstructured":"Bopp S, Magistrado P, Wong W, Schaffner SF, Mukherjee A, Lim P, Dhorda M, et al. Plasmepsin II\u2013III copy number accounts for bimodal piperaquine resistance among Cambodian Plasmodium falciparum. Nat Commun. 2018;9:1769.","journal-title":"Nat Commun"},{"key":"4181_CR31","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/infdis\/jix334","volume":"216","author":"S Agrawal","year":"2017","unstructured":"Agrawal S, Moser KA, Morton L, Cummings MP, Parihar A, Dwivedi A, et al. Association of a novel mutation in the Plasmodium falciparum chloroquine resistance transporter with decreased piperaquine sensitivity. J Infect Dis. 2017;216:468\u201376.","journal-title":"J Infect Dis"},{"key":"4181_CR32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12936-020-03249-x","volume":"19","author":"MR Ansbro","year":"2020","unstructured":"Ansbro MR, Jacob CG, Amato R, Kekre M, Amaratunga C, Sreng S, Suon S, et al. Development of copy number assays for detection and surveillance of piperaquine resistance associated plasmepsin 2\/3 copy number variation in Plasmodium falciparum. Malar J. 2020;19:181.","journal-title":"Malar J"},{"key":"4181_CR33","doi-asserted-by":"publisher","first-page":"e02309","DOI":"10.1128\/AAC.02309-17","volume":"62","author":"A Mukherjee","year":"2018","unstructured":"Mukherjee A, Gagnon D, Wirth DF, Richard D. Inactivation of plasmepsins 2 and 3 sensitizes Plasmodium falciparum to the antimalarial drug piperaquine. Antimicrob Agents Chemother. 2018;62:e02309-e2317.","journal-title":"Antimicrob Agents Chemother"},{"key":"4181_CR34","doi-asserted-by":"publisher","first-page":"8425","DOI":"10.1074\/jbc.REV120.009309","volume":"295","author":"AS Nasamu","year":"2020","unstructured":"Nasamu AS, Polino AJ, Istvan ES, Goldberg DE. Malaria parasite plasmepsins: more than just plain old degradative pepsins. J Biol Chem. 2020;295:8425\u201341.","journal-title":"J Biol Chem"},{"key":"4181_CR35","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/S1473-3099(19)30543-2","volume":"19","author":"SK Dhingra","year":"2019","unstructured":"Dhingra SK, Small-Saunders JL, M\u00e9nard D, Fidock DA. Plasmodium falciparum resistance to piperaquine driven by PfCRT. Lancet Infect Dis. 2019;19:1168\u20139.","journal-title":"Lancet Infect Dis"},{"key":"4181_CR36","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12936-020-03339-w","volume":"19","author":"N Boonyalai","year":"2020","unstructured":"Boonyalai N, Vesely BA, Thamnurak C, Praditpol C, Fagnark W, Kirativanich K, et al. Piperaquine resistant Cambodian Plasmodium falciparum clinical isolates: in vitro genotypic and phenotypic characterization. Malar J. 2020;19:269.","journal-title":"Malar J"},{"key":"4181_CR37","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12936-020-03358-7","volume":"19","author":"W Chebore","year":"2020","unstructured":"Chebore W, Zhou Z, Westercamp N, Otieno K, Shi YP, Sergent SB, et al. Assessment of molecular markers of anti-malarial drug resistance among children participating in a therapeutic efficacy study in western Kenya. Malar J. 2020;19:291.","journal-title":"Malar J"},{"key":"4181_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ijpddr.2018.11.004","volume":"9","author":"D Loesbanluechai","year":"2019","unstructured":"Loesbanluechai D, Kotanan N, de Cozar C, Kochakarn T, Ansbro MR, et al. Overexpression of plasmepsin II and plasmepsin III does not directly cause reduction in Plasmodium falciparum sensitivity to artesunate, chloroquine and piperaquine. Int J Parasitol Drugs Drug Resist. 2019;9:16\u201322.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"4181_CR39","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0140-6736(04)16767-6","volume":"364","author":"RN Price","year":"2004","unstructured":"Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet. 2004;364:438\u201347.","journal-title":"Lancet"},{"key":"4181_CR40","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1093\/gbe\/evx126","volume":"9","author":"CM Parobek","year":"2017","unstructured":"Parobek CM, Parr JB, Brazeau NF, Lon C, Chaorattanakawee S, Gosi P, et al. Partner-drug resistance and population substructuring of artemisinin-resistant Plasmodium falciparum in Cambodia. Genome Biol Evol. 2017;9:1673\u201386.","journal-title":"Genome Biol Evol"},{"key":"4181_CR41","doi-asserted-by":"publisher","first-page":"14552","DOI":"10.1038\/srep14552","volume":"5","author":"S Pulcini","year":"2015","unstructured":"Pulcini S, Staines HM, Lee AH, Shafik SH, Bouyer G, Moore CM, Daley DA, et al. Mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, enlarge the parasite\u2019s food vacuole and alter drug sensitivities. Sci Rep. 2015;5:14552.","journal-title":"Sci Rep"},{"key":"4181_CR42","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/infdis\/jiu141","volume":"210","author":"MD Conrad","year":"2014","unstructured":"Conrad MD, LeClair N, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, Muhindo M, et al. Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children. J Infect Dis. 2014;210:344\u201353.","journal-title":"J Infect Dis"},{"key":"4181_CR43","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1128\/AAC.06350-11","volume":"56","author":"MI Veiga","year":"2012","unstructured":"Veiga MI, Ferreira PE, Malmberg M, J\u00f6rnhagen L, Bj\u00f6rkman A, Nosten F, et al. pfmdr1 amplification is related to increased Plasmodium falciparum in vitro sensitivity to the bisquinoline piperaquine. Antimicrob Agents Chemother. 2012;56:3615\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"4181_CR44","doi-asserted-by":"publisher","first-page":"19809","DOI":"10.1038\/s41598-021-99192-1","volume":"11","author":"A Osborne","year":"2021","unstructured":"Osborne A, Manko E, Takeda M, Kaneko A, Kagaya W, Chan C, Ngara M, et al. Characterizing the genomic variation and population dynamics of Plasmodium falciparum malaria parasites in and around Lake Victoria. Kenya Sci Rep. 2021;11:19809.","journal-title":"Kenya Sci Rep"},{"key":"4181_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1009268","volume":"16","author":"A Turkiewicz","year":"2020","unstructured":"Turkiewicz A, Manko E, Sutherland CJ, Diez Benavente E, Campino S, Clark TG. Genetic diversity of the Plasmodium falciparum GTP-cyclohydrolase 1, dihydrofolate reductase and dihydropteroate synthetase genes reveals new insights into sulfadoxine-pyrimethamine antimalarial drug resistance. PLoS Genet. 2020;16: e1009268.","journal-title":"PLoS Genet"},{"key":"4181_CR46","doi-asserted-by":"publisher","first-page":"42","DOI":"10.12688\/wellcomeopenres.16168.1","volume":"6","author":"A Ahouidi","year":"2021","unstructured":"MalariaGEN, Ahouidi A, Ali M, Almagro-Garcia J, Amambua-Ngwa A, et al. An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Res. 2021;6:42.","journal-title":"Wellcome Open Res"},{"key":"4181_CR47","volume-title":"Technical expert group (TEG) on drug efficacy and response","author":"WHO and Technical Expert Group","year":"2015","unstructured":"WHO and Technical Expert Group. Technical expert group (TEG) on drug efficacy and response. Geneva: World Health Organization; 2015."},{"key":"4181_CR48","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12936-019-2906-8","volume":"18","author":"TP Eisele","year":"2019","unstructured":"Eisele TP. Mass drug administration can be a valuable addition to the malaria elimination toolbox. Malar J. 2019;18:281.","journal-title":"Malar J"},{"key":"4181_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002124","volume":"13","author":"M Madanitsa","year":"2016","unstructured":"Madanitsa M, Kalilani L, Mwapasa V, van Eijk AM, Khairallah C, Ali D, et al. Scheduled intermittent screening with rapid diagnostic tests and treatment with dihydroartemisinin-piperaquine versus intermittent preventive therapy with sulfadoxine-pyrimethamine for malaria in pregnancy in Malawi: an open-label randomized controlled trial. PLoS Med. 2016;13: e1002124.","journal-title":"PLoS Med"},{"key":"4181_CR50","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1093\/infdis\/jiv249","volume":"212","author":"F Huang","year":"2015","unstructured":"Huang F, Takala-Harrison S, Jacob CG, Liu H, Sun X, Yang H, Nyunt MM, et al. A Single mutation in K13 predominates in southern China and is associated with delayed clearance of Plasmodium falciparum following artemisinin treatment. J Infect Dis. 2015;212:1629\u201335.","journal-title":"J Infect Dis"},{"key":"4181_CR51","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/S1473-3099(20)30228-0","volume":"20","author":"M Imwong","year":"2020","unstructured":"Imwong M, Dhorda M, Myo Tun K, Thu AM, Phyo AP, Proux S, Suwannasin K, et al. Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. Lancet Infect Dis. 2020;20:1470\u201380.","journal-title":"Lancet Infect Dis"},{"key":"4181_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240174","volume":"15","author":"H Gupta","year":"2020","unstructured":"Gupta H, Galatas B, Chidimatembue A, Huijben S, Cister\u00f3 P, Matambisso G, et al. Effect of mass dihydroartemisinin-piperaquine administration in southern Mozambique on the carriage of molecular markers of antimalarial resistance. PLoS ONE. 2020;15: e0240174.","journal-title":"PLoS ONE"},{"key":"4181_CR53","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1093\/infdis\/jix421","volume":"216","author":"MD Conrad","year":"2017","unstructured":"Conrad MD, Mota D, Foster M, Tukwasibwe S, Legac J, Tumwebaze P, et al. Impact of intermittent preventive treatment during pregnancy on Plasmodium falciparum drug resistance-mediating polymorphisms in Uganda. J Infect Dis. 2017;216:1008\u201317.","journal-title":"J Infect Dis"},{"key":"4181_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002745","volume":"16","author":"L von Seidlein","year":"2019","unstructured":"von Seidlein L, Peto TJ, Landier J, Nguyen TN, Tripura R, Phommasone K, et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: a cluster randomised trial. PLoS Med. 2019;16: e1002745.","journal-title":"PLoS Med"},{"key":"4181_CR55","doi-asserted-by":"publisher","first-page":"81","DOI":"10.12688\/wellcomeopenres.12240.1","volume":"2","author":"J Landier","year":"2017","unstructured":"Landier J, Kajeechiwa L, Thwin MM, Parker DM, Chaumeau V, Wiladphaingern J, et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of eastern Myanmar. Wellcome Open Res. 2017;2:81.","journal-title":"Wellcome Open Res"},{"key":"4181_CR56","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12936-019-2756-4","volume":"18","author":"D Leroy","year":"2019","unstructured":"Leroy D, Macintyre F, Adoke Y, Ouoba S, Barry A, Mombo-Ngoma G, et al. African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker. Malar J. 2019;18:126.","journal-title":"Malar J"},{"key":"4181_CR57","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S1473-3099(17)30048-8","volume":"17","author":"M Imwong","year":"2017","unstructured":"Imwong M, Suwannasin K, Kunasol C, Sutawong K, Mayxay M, Rekol H, et al. The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study. Lancet Infect Dis. 2017;17:491\u20137.","journal-title":"Lancet Infect Dis"},{"key":"4181_CR58","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1186\/s12936-017-2091-6","volume":"16","author":"DH Son","year":"2017","unstructured":"Son DH, Thuy-Nhien N, von Seidlein L, Le Phuc-Nhi T, Phu NT, Tuyen NTK, et al. The prevalence, incidence and prevention of Plasmodium falciparum infections in forest rangers in Bu Gia Map National Park, Binh Phuoc province, Vietnam: a pilot study. Malar J. 2017;16:444.","journal-title":"Malar J"},{"key":"4181_CR59","doi-asserted-by":"publisher","first-page":"e01047","DOI":"10.1128\/AAC.01047-20","volume":"64","author":"P Nayebare","year":"2020","unstructured":"Nayebare P, Asua V, Conrad MD, Kajubi R, Kakuru A, Nankabirwa JI, et al. Associations between malaria-preventive regimens and Plasmodium falciparum drug resistance-mediating polymorphisms in Ugandan pregnant women. Antimicrob Agents Chemother. 2020;64:e01047-e1120.","journal-title":"Antimicrob Agents Chemother"},{"key":"4181_CR60","doi-asserted-by":"publisher","first-page":"e01393","DOI":"10.1128\/AAC.01393-18","volume":"63","author":"E Wallender","year":"2019","unstructured":"Wallender E, Zhang N, Conrad M, Kakuru A, Muhindo M, Tumwebaze P, et al. Modeling prevention of malaria and selection of drug resistance with different dosing schedules of dihydroartemisinin-piperaquine preventive therapy during pregnancy in Uganda. Antimicrob Agents Chemother. 2019;63:e01393-e1418.","journal-title":"Antimicrob Agents Chemother"},{"key":"4181_CR61","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1128\/AAC.04923-14","volume":"59","author":"I Zongo","year":"2015","unstructured":"Zongo I, Milligan P, Compaore YD, Some AF, Greenwood B, Tarning J, et al. Randomized noninferiority trial of dihydroartemisinin-piperaquine compared with sulfadoxine-pyrimethamine plus amodiaquine for seasonal malaria chemoprevention in Burkina Faso. Antimicrob Agents Chemother. 2015;59:4387\u201396.","journal-title":"Antimicrob Agents Chemother"},{"key":"4181_CR62","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1128\/AAC.02406-14","volume":"58","author":"AF Som\u00e9","year":"2014","unstructured":"Som\u00e9 AF, Zongo I, Compaor\u00e9 YD, Sakand\u00e9 S, Nosten F, Ou\u00e9draogo JB, Rosenthal PJ. Selection of drug resistance-mediating Plasmodium falciparum genetic polymorphisms by seasonal malaria chemoprevention in Burkina Faso. Antimicrob Agents Chemother. 2014;58:3660\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"4181_CR63","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1128\/AAC.05141-14","volume":"99","author":"P Tumwebaze","year":"2015","unstructured":"Tumwebaze P, Jagannathan P, Legac J, Mota D, Tukwasibwe S, Whalen M, et al. Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from Ugandan Children. Antimicrob Agents Chemother. 2015;59:3018\u201330.","journal-title":"Antimicrob Agents Chemother"},{"key":"4181_CR64","doi-asserted-by":"publisher","first-page":"ofw229","DOI":"10.1093\/ofid\/ofw229","volume":"4","author":"AR Taylor","year":"2016","unstructured":"Taylor AR, Flegg JA, Holmes CC, Gu\u00e9rin PJ, Sibley CH, Conrad MD, et al. Artemether-lumefantrine and dihydroartemisinin-piperaquine exert inverse selective pressure on Plasmodium falciparum drug sensitivity-associated haplotypes in Uganda. Open Forum Infect Dis. 2016;4:ofw229.","journal-title":"Open Forum Infect Dis"},{"key":"4181_CR65","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1128\/AAC.00161-13","volume":"57","author":"E Ochong","year":"2013","unstructured":"Ochong E, Tumwebaze PK, Byaruhanga O, Greenhouse B, Rosenthal PJ. Fitness consequences of Plasmodium falciparum pfmdr1 polymorphisms inferred from ex vivo culture of ugandan parasites. Antimicrob Agents Chemother. 2013;57:4245\u201351.","journal-title":"Antimicrob Agents Chemother"},{"key":"4181_CR66","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/cid\/ciy196","volume":"67","author":"R Tripura","year":"2018","unstructured":"Tripura R, Peto TJ, Chea N, Chan D, Mukaka M, Sirithiranont P, et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clin Infect Dis. 2018;67:817\u201326.","journal-title":"Clin Infect Dis"},{"key":"4181_CR67","first-page":"1670","volume":"67","author":"C Deng","year":"2018","unstructured":"Deng C, Huang B, Wang Q, Wu W, Zheng S, Zhang H, et al. Large-scale artemisinin-piperaquine mass drug administration with or without primaquine dramatically reduces malaria in a highly endemic region of Africa. Clin Infect Dis. 2018;67:1670\u20136.","journal-title":"Clin Infect Dis"},{"key":"4181_CR68","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12916-017-0940-3","volume":"15","author":"F Macintyre","year":"2017","unstructured":"Macintyre F, Adoke Y, Tiono AB, Duong TT, Mombo-Ngoma G, Bouyou-Akotet M, et al. A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria. BMC Med. 2017;15:181.","journal-title":"BMC Med"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04181-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-022-04181-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04181-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T10:11:23Z","timestamp":1655806283000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-022-04181-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,11]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4181"],"URL":"https:\/\/doi.org\/10.1186\/s12936-022-04181-y","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,11]]},"assertion":[{"value":"17 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"186"}}